Clinical Trials Logo

Deafness clinical trials

View clinical trials related to Deafness.

Filter by:
  • Enrolling by invitation  
  • « Prev · Page 2

NCT ID: NCT04673565 Enrolling by invitation - Hearing Loss Clinical Trials

Motivational Interviewing in Hearing Aid Users

MI-HAT
Start date: March 16, 2021
Phase: N/A
Study type: Interventional

Hearing loss is one of the most common chronic disabilities in the older adult population and affects their quality of life. Hearing aid use can improve one's quality of life by increasing a person's ability to detect, differentiate and locate sound, and improve speech recognition. Several factors seem to reduce motivation to use a hearing aid. Fears of exclusion and shame due to hearing loss are major deterrents to hearing aid use. Motivational interviewing (MI) is a counselling style aimed at creating desire in patients to change their behavior. There have been pilot studies that suggest one-on-one MI can increase hearing aid use, but other pilot studies found the reverse hence the evidence is inconclusive. The effectiveness of group MI therapy is also being investigated in MI research. While results in group MI research are promising, studies investigating group MI have been limited to substance abuse.

NCT ID: NCT04672174 Enrolling by invitation - Clinical trials for Hearing Loss, Sensorineural

Cognitive Screening Of Patients With Hearing Loss

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

Hearing loss and cognitive impairment both appear in elderly patients. The goal was to use a modified screening method added to already established cognitive tests to obtain a standardized test for detection of cognitive impairment in patients with hearing loss. The aim of this study is to collect data with neuropsychological tests using questionnaires and to determine cognitive impairment in patients with hearing loss. The collected data will be evaluated using SPSS 23. The corrected item-total correlation and item difficulty of the item DemTectEar will be assessed by item analysis / Cronbachs' Alpha. For further evaluation and comparisons two-sided t-tests with a level of significance 0.05 or Mann-Whitney-U-tests will be performed.

NCT ID: NCT04183361 Enrolling by invitation - Clinical trials for Sensorineural Hearing Loss

ABR Characteristics and Salivary Cortisone Concentration in Noise-exposed Workers

Start date: November 1, 2019
Phase:
Study type: Observational

The aim of the research: Investigate the association of auditory evoked brainstem response characteristics with salivary cortisone concentrations in noise-exposed workers. Purpose of the research: 1. Investigate the magnitude of the amplitudes and latencies of auditory brainstem responses. 2. Investigate the concentration of cortisone in saliva. 3. To investigate the correlation of the characteristics of auditory evoked brainstem potentials with the age of the subjects or the length of work in noise. 4. Investigate the association of salivary cortisone concentration with subjects' age or length of work in noise. 5. Investigate the prevalence of mild, moderate and severe hearing impairment in the 19-35 age group. 6. Investigate the relationship of hearing threshold shift with the age of the subjects or the length of work in noise. 7. To investigate the difference in the characteristics of auditory evoked brainstem potentials and the difference in salivary cortisone concentration between subjects with a bilaterally normal hearing threshold (≤25 dB) at high frequencies and subjects with unilaterally or bilaterally increased hearing threshold (> 25 dB) at high frequencies . 8. Investigate the perceived stress and psychosocial risk factors in the workplace and their relationship to salivary cortisone concentrations. Research Hypothesis: There is an association between the characteristics of auditory evoked brainstem response and salivary cortisone concentrations in noise-exposed workers. Research participants Inclusion criteria: 1. male and female 2. ages 19-35 3. exposure to noise level ≥ 85 dB (A) per week at the workplace 4. work in noise from 1 to 16 years 5. workplace not involving exposure to carbon disulfide or a mixture of organic solvents that have toxic effects on the ear (toluene, xylene and styrene) 6. unilaterally or bilaterally normal otoscopic findings 7. unilaterally or bilaterally tympanogram: peak pressure value ± 50 daPa at 226 Hz with eardrum mobility of 0.3 to 1.3 mL Exclusion criteria: 1. information about an earlier sudden hearing loss 2. information on chronic middle ear inflammation 3. information on ear surgery (except placement of ventilation tubes in the eardrum) 4. information on dizziness associated with hearing loss and noise 5. information on insomnia 6. current use of oral corticosteroids 7. bilaterally found air-bone gap greater than 15 dB

NCT ID: NCT04161261 Enrolling by invitation - Hearing Loss Clinical Trials

Minimizing Facial Nerve Stimulation in Cochlear Implants

Start date: December 13, 2019
Phase: N/A
Study type: Interventional

This study aims to understand how to manipulate the electrical stimulation from the cochlear implant to maximize hearing stimulation and minimize facial stimulation. It is know from animal data that the hearing and facial nerves have different sensitivities to things like electrical pulse shape, its pattern, and its duration. It is very unclear however if this applies to human cochlear implant patients, and what the optimal parameters are to selectively stimulate the hearing nerve in humans. The outcomes of this study will be used to more selectively program some patients with severe facial nerve cross stimulation and to inform the development of new types of implant stimulation.

NCT ID: NCT01333683 Enrolling by invitation - Hearing Loss Clinical Trials

Tinnitus and Arterial Hypertension

Start date: April 2011
Phase: N/A
Study type: Observational

Many authors link tinnitus to arterial hypertension. The aim of this study is to establish a possible relationship between them, analyze the severity of tinnitus related to arterial hypertension and analyze a possible influence of ototoxic drugs used to treat arterial hypertension

NCT ID: NCT00341874 Enrolling by invitation - Hearing Disorder Clinical Trials

Genetic Analyses of Nonsyndromic and Syndromic Deafness in Pakistan

Start date: March 16, 2000
Phase:
Study type: Observational

Objective: One objective of this study is to genetically map and identify mutated genes for human hereditary hearing loss. A second objective is to study the function of these genes in the auditory system using mouse models. Human hereditary hearing impairment is the result of abnormal ear development, abnormal ear function or both. Although the genes for numerous deafness loci have been mapped and identified, there are still many families segregating deafness as a monogenic trait but a mutant allele can t be ascribed to one of the currently reported deafness genes . In order to map and identify novel mutated genes associated with hearing loss in humans, we will continue to ascertain large families segregating syndromic and nonsyndromic deafness as a monogenic trait. Study population: This study will ascertain subjects from consanguineous Pakistani families segregating hearing loss consisting of both nonsyndromic and syndromic forms of deafness of genetic etiology. Since a majority of Pakistani marriages are between first cousins, this tends to bring together the same recessive mutations for hearing loss with multiple affected individuals within single family lines, which is an advantage for this genetic study. A few years ago we stopped ascertaining families in India. We continue to ascertain both affected and unaffected Pakistani family members from age 2 years and up. Adults provide informed consent both for themselves and their children who agree to participate in this study. We will ascertain both genders and all Pakistani races and ethnicities. Design: Subjects will be screened and consented by our collaborating Associate Investigator in Pakistan. After consenting, the subjects will undergo a history and physical, audiological assessment and testing, vestibular assessment and testing, and blood and urine analysis tests, along with a blood sample or buccal swab sample that will be used for genomic DNA extraction. Probands at the time of ascertainment are initially assumed to have a form of nonsyndromic deafness. Additional tests may be performed depending on the history or physical of the individual or after the deafness gene is identified. Data from functional studies in animal models may also point to other concomitant clinical features along with hearing loss. These additional tests may include: photographs or videotapes of a subject s body and face; eye and vision examinations for those with suspected or known eyesight problems related to their genetic hearing loss mutations, and EKGs and/or Echocardiograms for those with suspected or known heart problems related to their genetic hearing loss mutations. Urine and blood analyses may be requested for those individuals with genetic nephritic issues or infertility. For example, when a deaf female individual in a family is subsequently discovered to have Perrault syndrome, a recessive disorder characterized by hearing loss (usually the initial manifestation) and ovarian dysgenesis/primary amenorrhea, additional evaluations would then be conducted for a definitive diagnosis of Perrault syndrome. Such an evaluation would include a pelvic ultrasound scan and measurements of serum estrogen and gonadotropins. Similarly, in some of these families, hearing impaired males may be asked about their fertility since the possibility of male infertility in families segregating Perrault syndrome remains an open question. For genetic analyses, genomic DNA extracted from a blood sample or a buccal swab from affected and unaffected members of families segregating hereditary hearing loss will be genetically screened with polymorphic markers (STRs or SNPs) for linkage to the known deafness loci. The hearing phenotype of children (>2 years old), adolescent and adult subjects will be assigned on the basis of performance from audiological examinations. Genomic DNA from families where deafness is found to be unlinked to the known deafness loci will then be used in genome wide screens with approximately 950,000 SNP markers distributed across the entire human genome to identify novel deafness loci. Alternatively, DNA samples from affected and unaffected individuals will undergo whole exome sequencing (WES) or whole genome sequencing (WGS) with a focus on potentially pathogenic variants located only in chromosomal regions of markers genetically linked to deafness. Subsequently, novel deafness genes will be positionally identified and their functions studied. Outcome measures: Novel deafness loci and genes associated with hearing loss will be identified and will provide new insight into mechanisms required for sound transduction in humans. Data from this study is likely to be the basis of commercially available tests for early diagnosis and timely genetic counseling for at risk couples as well as the development of strategies to preserve hearing and prevent hearing loss.